Vitronectin receptor antagonists
CA 2303487 A1 · Owner: Heerding, Dirk · Inventors: Heerding, Dirk; Samanen, James Martin; Miller, William H.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Compounds of formula (I) are disclosed which are vitronectin receptor antagonists and are useful in the treatment of osteoporosis wherein: A is CH2 or O; R1 is H, halo or C1-6alkyl; R2 is H C1-6alkyl or CH2NR''R''; X is O or , CH2; Y is (a) (b), (c), (d), (e), (f) or (g); G is NR'' S or O; R' is H, C1-, 6alkyl, OC1-6alkyl SC1-6alkyl, NR''R'' or halo; each R'' independently is H or C1-6alkyl; and s is 0, 1 or 2; or a pharmaceutically acceptable salt thereof.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 18, 1998. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended September 18, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 18, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.